Lenvatinib Clinical Trials (75 Recruiting)

Showing 1–20 of 84 trials

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Merck Sharp & Dohme LLC3,500 enrolled781 locationsNCT03486873

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

CatalYm GmbH104 enrolled14 locationsNCT07219459

Recruiting

Phase 2

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy

Peking Union Medical College Hospital70 enrolled1 locationNCT07704177

Recruiting

Phase 2

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

Canadian Cancer Trials Group140 enrolled12 locationsNCT06880523

Recruiting

Phase 2

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Recurrent Endometrial Cancer

University of Miami46 enrolled1 locationNCT07594015

Recruiting

Phase 1Phase 2

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center56 enrolled7 locationsNCT06110793

Recruiting

Phase 2

Merck IIT: RRP Pembro and Lenvatinib

Pulmonary DiseaseRecurrent Respiratory PapillomatosisHuman Papilloma Virus

Yale University20 enrolled1 locationNCT04645602

Recruiting

Phase 1Phase 2

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma

Glenn J. Hanna32 enrolled1 locationNCT05774899

Recruiting

Phase 2

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy

Peking Union Medical College Hospital70 enrolled1 locationNCT07670273

Recruiting

Phase 1Phase 2

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Merck Sharp & Dohme LLC230 enrolled59 locationsNCT05319730

Recruiting

Phase 2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more

NRG Oncology240 enrolled328 locationsNCT05327686

Recruiting

Phase 3

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+1 more

SWOG Cancer Research Network718 enrolled41 locationsNCT07383441

Recruiting

Phase 2

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd.74 enrolled1 locationNCT06986785

Recruiting

Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Solid Tumor

Eisai Inc.182 enrolled58 locationsNCT04300556

Recruiting

Phase 2

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

Hepatocellular Carcinoma (HCC)

CHA University80 enrolled1 locationNCT07493668

Recruiting

Phase 1Phase 2

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more

GI Innovation, Inc.317 enrolled12 locationsNCT04977453

Recruiting

Phase 2

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

Clear Cell RCC

Jinling Hospital, China75 enrolled1 locationNCT07571551

Recruiting

Phase 2

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Recurrent Vulvar CancerPersistent Vulvar CancerMetastatic Vulva Cancer+1 more

AGO Research GmbH42 enrolled15 locationsNCT05903833

Recruiting

Phase 2

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Cervical CancerCervix Cancer

University of Texas Southwestern Medical Center30 enrolled1 locationNCT06266338

Lenvatinib Clinical Trials

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Merck IIT: RRP Pembro and Lenvatinib

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)